Stocks That Hit 52-Week Lows On Friday
During Friday's session, 445 companies made new 52-week lows.
Assembly Biosciences Outlines Anticipated 2022 Pipeline Development Milestones
Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today outlined anticipated progress and
12 Health Care Stocks Moving In Thursday’s After-Market Session
Gainers
XTL Biopharmaceuticals (NASDAQ:XTLB) shares rose 17.74% to $3.65 during Thursday's after-market session. The market value of their outstanding shares is at $19.2 million.
Assembly Biosciences Abstracts Selected For Presentation At Upcoming AASLD The Liver Meeting
Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced that clinical and preclinical data from its HBV
Antios Therapeutics And Assembly Biosciences Announce Clinical Collaboration Agreement To Evaluate The Combination Of ATI-2173 And Vebicorvir In Patients With Chronic Hepatitis B Virus Infection
Antios Therapeutics, Inc. and Assembly Biosciences, Inc. (NASDAQ:ASMB) today announced that the companies have entered into a clinical collaboration agreement to evaluate a triple combination treatment in patients with
HC Wainwright & Co. Initiates Coverage On Assembly Biosciences with Neutral Rating, Announces Price Target of $3.5
HC Wainwright & Co. analyst Ed Arce initiates coverage on Assembly Biosciences (NASDAQ:ASMB) with a Neutral rating and announces Price Target of $3.5.